3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow

Published June 14, 2026 · Category: Finance

Overview

There are some good reasons why investors might want to avoid Eli Lilly (NYSE: LLY). For example, its price-to-earnings ratio is high at 40x, and its yield is very low at just 0.6%. But there are also some very good reasons to buy the drug maker's shares, noting that it is a leader in the merging GLP-1 weight-loss market. Here are three reasons to buy Eli Lilly as it looks to leverage its success to create a brighter tomorrow.

Eli Lilly's P/E ratio is high for a very good reason. It was second to market with a GLP-1 shot, but it quickly overtook Novo Nordisk (NYSE: NVO), which was the first to market with a GLP-1 shot (Wegovy). And the sales growth Eli Lilly's Mounjaro and Zepbound have achieved is nothing short of incredible.

Image source: Getty Images.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• SpaceX shows investors still want moonshots. The Fed may test that theory this week.
• Top Wall Street analysts are confident about the growth prospects of these 3 stocks
• The World Cup could add $17 billion to the U.S. economy. Here are the stocks set to benefit